Total intravenous anesthesia with remifentanil, propofol and cisatracurium in end-stage renal failure

被引:24
|
作者
Dahaba, AA
von Klobucar, F
Rehak, PH
List, WF
机构
[1] Karl Franzens Univ Graz, Dept Anesthesiol & Intens Care Med, Graz, Austria
[2] Karl Franzens Univ Graz, Dept Surg, Biomed Engn & Comp Unit, Graz, Austria
关键词
D O I
10.1007/BF03013962
中图分类号
R614 [麻醉学];
学科分类号
100217 ;
摘要
Purpose: To compare recovery parameters of total intravenous anesthesia (TIVA) with remifentanil and propofol, hemodynamic responses to perioperative events, and pharmacodynamic parameters of cisatracurium in 22 end-stage renal failure and 22 normal renal function patients. Methods: Anesthesia was induced with 2-3 mg.kg(-1) propofol and 1 mu g.kg(-1) remifentanil and maintained with 75 mu g.kg(-1).min(-1) propofol and propofol initial infusion of 0.2 mu g.kg(-1).min(-1) propofol. Arterial pressure and heart rate were maintained by remifentanil infusion rate adjustments. The first twitch (TI) was maintained at 25% by an infusion-of cisatracurium. Results: There was no difference in the time to maintenance of adequate respiration, date of birth recollection, first analgesic administration, between the renal failure (4.8 +/- 2.5, 7.8 +/- 3.2, 12.3 +/- 5.3 min respectively) and the control group (5.2 +/- 2.8, 8.1 +/- 3.1, 12.7 +/- 5.5 min): nor were there any differences in the time to 25% TI recovery, TI recovery from 25% to 75%, or cisatracurium infusion rate between the renal failure group (32.1 +/- 10.8 min, 18.2 +/- 5.5 min; 0.89 +/- 0.29 mu g.kg(-1).min(-1) respectively) and the control group (35.9 (7.9 min, 18.4 +/- 3.8 min, 0.95 +/- 0.22 mu g.kg(-1).min(-1)). Conclusion: End-stage renal failure does not prolong recovery from TIVA with remifentanil and propofol, or the recovery from cisatracurium neuromuscular block.
引用
收藏
页码:696 / 700
页数:5
相关论文
共 50 条
  • [41] Relationship between decrement time and recovery time in pediatric total intravenous anesthesia with propofol and remifentanil
    Bagshaw, Oliver
    PEDIATRIC ANESTHESIA, 2023, 33 (06) : 486 - 491
  • [42] SOTALOL AND END-STAGE RENAL-FAILURE
    PATRICK, GM
    POLLOCK, CA
    EBELS, LS
    CATERSON, RJ
    KIDNEY INTERNATIONAL, 1994, 45 (04) : 1268 - 1268
  • [43] PREVENTION OF END-STAGE RENAL-FAILURE
    KINMONTH, AL
    SMELLIE, JM
    BRITISH JOURNAL OF GENERAL PRACTICE, 1995, 45 (393): : 219 - 219
  • [44] SOTALOL AND END-STAGE RENAL-FAILURE
    PATRICK, GM
    POLLOCK, CA
    IBELS, LS
    CATERSON, RJ
    AUSTRALIAN AND NEW ZEALAND JOURNAL OF MEDICINE, 1994, 24 (03): : 319 - 320
  • [45] THE LAW AND END-STAGE RENAL-FAILURE
    HEATH, PJ
    LANCET, 1984, 1 (8378): : 682 - 682
  • [46] Comparison of the recovery and respiratory effects of aminophylline and doxapram following total intravenous anesthesia with propofol and remifentanil
    Kim, Dae Woo
    Joo, Jin Deok
    In, Jang Hyeok
    Jeon, Yeon Su
    Jung, Hong Soo
    Jeon, Kyeong Bae
    Park, Jae Sik
    Choi, Jin Woo
    JOURNAL OF CLINICAL ANESTHESIA, 2013, 25 (03) : 173 - 176
  • [47] END-STAGE RENAL-FAILURE IN DIABETICS
    DAGGETT, P
    LANCET, 1985, 1 (8426): : 466 - 466
  • [48] DIABETES AND END-STAGE RENAL-FAILURE
    CATALANO, C
    CUZZOLA, F
    ENIA, G
    MAGGIORE, Q
    LANCET, 1987, 1 (8543): : 1201 - 1201
  • [49] END-STAGE RENAL-FAILURE IN DIABETES
    SCOTT, SJ
    MCHUGH, MI
    MARTIN, AM
    LANCET, 1986, 2 (8521-2): : 1466 - 1467
  • [50] End-stage renal failure and management of diabetes
    Bilous, RW
    DIABETIC MEDICINE, 2004, 21 : 12 - 14